Collectively, these findings demonstrate that elevated UBE2V1 expression promotes tumor cell proliferation and metastasis, which aligns with clinical observations linking high UBE2V1 levels to poor patient prognosis, suggesting its importance as an oncogenic driver and a potential therapeutic target in HCC progression. Here, UBE2V1 is linked to hepatocellular carcinoma.